Literature DB >> 2138908

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study.

G Blackledge1, A van Oosterom, H Mouridsen, W P Steward, J Buesa, D Thomas, R Sylvester, J Rouesse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2138908     DOI： 10.1016/0277-5379(90)90296-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

Authors:  O S Nielsen; P Dombernowsky; H Mouridsen; D Crowther; J Verweij; J Buesa; W Steward; S Daugaard; M van Glabbeke; A Kirkpatrick; T Tursz
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

2.  A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.

Authors:  Joanna Vitfell-Rasmussen; Ian Judson; Akmal Safwat; Robin L Jones; Philip Blach Rossen; Maja Lind-Hansen; Poul Knoblauch; Anders Krarup-Hansen
Journal:  Sarcoma       Date:  2016-06-14

3.  Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  O S Nielsen; P Dombernowsky; H Mouridsen; S Daugaard; M Van Glabbeke; A Kirkpatrick; J Verweij
Journal:  Sarcoma       Date:  2000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.